S&P 500   4,580.42 (+1.49%)
DOW   34,661.25 (+1.88%)
QQQ   390.57 (+0.89%)
AAPL   163.19 (-0.96%)
MSFT   331.22 (+0.35%)
FB   309.31 (-0.42%)
GOOGL   2,862.03 (+1.45%)
AMZN   3,458.49 (+0.43%)
TSLA   1,091.19 (-0.35%)
NVDA   323.59 (+2.94%)
BABA   124.07 (+1.29%)
NIO   37.07 (-3.24%)
CGC   10.13 (+1.91%)
AMD   150.99 (+1.26%)
GE   94.81 (+1.95%)
MU   83.09 (-2.42%)
T   23.00 (+3.46%)
F   20.04 (+2.35%)
DIS   146.78 (+3.26%)
PFE   53.65 (-1.88%)
AMC   30.14 (+5.50%)
ACB   6.04 (+0.50%)
BA   198.92 (+5.70%)
S&P 500   4,580.42 (+1.49%)
DOW   34,661.25 (+1.88%)
QQQ   390.57 (+0.89%)
AAPL   163.19 (-0.96%)
MSFT   331.22 (+0.35%)
FB   309.31 (-0.42%)
GOOGL   2,862.03 (+1.45%)
AMZN   3,458.49 (+0.43%)
TSLA   1,091.19 (-0.35%)
NVDA   323.59 (+2.94%)
BABA   124.07 (+1.29%)
NIO   37.07 (-3.24%)
CGC   10.13 (+1.91%)
AMD   150.99 (+1.26%)
GE   94.81 (+1.95%)
MU   83.09 (-2.42%)
T   23.00 (+3.46%)
F   20.04 (+2.35%)
DIS   146.78 (+3.26%)
PFE   53.65 (-1.88%)
AMC   30.14 (+5.50%)
ACB   6.04 (+0.50%)
BA   198.92 (+5.70%)
S&P 500   4,580.42 (+1.49%)
DOW   34,661.25 (+1.88%)
QQQ   390.57 (+0.89%)
AAPL   163.19 (-0.96%)
MSFT   331.22 (+0.35%)
FB   309.31 (-0.42%)
GOOGL   2,862.03 (+1.45%)
AMZN   3,458.49 (+0.43%)
TSLA   1,091.19 (-0.35%)
NVDA   323.59 (+2.94%)
BABA   124.07 (+1.29%)
NIO   37.07 (-3.24%)
CGC   10.13 (+1.91%)
AMD   150.99 (+1.26%)
GE   94.81 (+1.95%)
MU   83.09 (-2.42%)
T   23.00 (+3.46%)
F   20.04 (+2.35%)
DIS   146.78 (+3.26%)
PFE   53.65 (-1.88%)
AMC   30.14 (+5.50%)
ACB   6.04 (+0.50%)
BA   198.92 (+5.70%)
S&P 500   4,580.42 (+1.49%)
DOW   34,661.25 (+1.88%)
QQQ   390.57 (+0.89%)
AAPL   163.19 (-0.96%)
MSFT   331.22 (+0.35%)
FB   309.31 (-0.42%)
GOOGL   2,862.03 (+1.45%)
AMZN   3,458.49 (+0.43%)
TSLA   1,091.19 (-0.35%)
NVDA   323.59 (+2.94%)
BABA   124.07 (+1.29%)
NIO   37.07 (-3.24%)
CGC   10.13 (+1.91%)
AMD   150.99 (+1.26%)
GE   94.81 (+1.95%)
MU   83.09 (-2.42%)
T   23.00 (+3.46%)
F   20.04 (+2.35%)
DIS   146.78 (+3.26%)
PFE   53.65 (-1.88%)
AMC   30.14 (+5.50%)
ACB   6.04 (+0.50%)
BA   198.92 (+5.70%)
NASDAQ:VYGR

Voyager Therapeutics Stock Forecast, Price & News

$2.87
-0.03 (-1.03%)
(As of 12/2/2021 12:22 PM ET)
Add
Compare
Today's Range
$2.81
$2.92
50-Day Range
$2.47
$5.55
52-Week Range
$2.46
$9.69
Volume
8,448 shs
Average Volume
1.91 million shs
Market Capitalization
$108.94 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.21
30 days | 90 days | 365 days | Advanced Chart
Receive VYGR News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Voyager Therapeutics logo

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.

Headlines

Voyager Flat Ahead of Data Presentation
November 19, 2021 |  baystreet.ca
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
177
Year Founded
N/A

Sales & Book Value

Annual Sales
$171.13 million
Cash Flow
$0.89 per share
Book Value
$2.30 per share

Profitability

Net Income
$36.74 million
Net Margins
-584.71%
Pretax Margin
-584.70%

Debt

Price-To-Earnings

Miscellaneous

Free Float
28,316,000
Market Cap
$108.94 million
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
12/02/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/24/2022

MarketRank

Overall MarketRank

2.22 out of 5 stars

Medical Sector

364th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

58th out of 202 stocks

Analyst Opinion: 3.2Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












Voyager Therapeutics (NASDAQ:VYGR) Frequently Asked Questions

Is Voyager Therapeutics a buy right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last year. There are currently 6 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Voyager Therapeutics stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in VYGR, but not buy additional shares or sell existing shares.
View analyst ratings for Voyager Therapeutics
or view top-rated stocks.

How has Voyager Therapeutics' stock price been impacted by COVID-19?

Voyager Therapeutics' stock was trading at $9.43 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, VYGR stock has decreased by 69.6% and is now trading at $2.87.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a decrease in short interest in the month of November. As of November 15th, there was short interest totaling 1,730,000 shares, a decrease of 27.9% from the October 31st total of 2,400,000 shares. Based on an average daily trading volume, of 5,500,000 shares, the days-to-cover ratio is presently 0.3 days. Currently, 6.7% of the company's stock are sold short.
View Voyager Therapeutics' Short Interest
.

When is Voyager Therapeutics' next earnings date?

Voyager Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Voyager Therapeutics
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) announced its quarterly earnings results on Tuesday, November, 2nd. The company reported ($0.67) EPS for the quarter, beating the Zacks' consensus estimate of ($0.75) by $0.08. Voyager Therapeutics had a negative trailing twelve-month return on equity of 76.02% and a negative net margin of 584.71%.
View Voyager Therapeutics' earnings history
.

What price target have analysts set for VYGR?

11 brokers have issued 12 month target prices for Voyager Therapeutics' stock. Their forecasts range from $4.00 to $45.00. On average, they anticipate Voyager Therapeutics' stock price to reach $12.78 in the next twelve months. This suggests a possible upside of 345.2% from the stock's current price.
View analysts' price targets for Voyager Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Voyager Therapeutics' key executives?

Voyager Therapeutics' management team includes the following people:
  • Michael J. Higgins, Chairman & Chief Executive Officer
  • Allison Dorval, CFO & Principal Accounting Officer
  • Glenn F. Pierce, Chief Scientific Officer & Director
  • Robert W. Hesslein, Senior Vice President & General Counsel
  • Allen Nunnally, Chief Business Officer

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

What is Voyager Therapeutics' stock symbol?

Voyager Therapeutics trades on the NASDAQ under the ticker symbol "VYGR."

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (2.45%), Morgan Stanley (1.63%), EcoR1 Capital LLC (1.17%), Renaissance Technologies LLC (0.83%), Millennium Management LLC (0.72%) and Fiduciary Trust Co. (0.65%). Company insiders that own Voyager Therapeutics stock include Allison Dorval, Andre Turenne, Matthew P Ottmer, Omar Khwaja and Robert W Hesslein.
View institutional ownership trends for Voyager Therapeutics
.

Which institutional investors are selling Voyager Therapeutics stock?

VYGR stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Goldman Sachs Group Inc., Morgan Stanley, Citadel Advisors LLC, Two Sigma Advisers LP, Renaissance Technologies LLC, Squarepoint Ops LLC, and Assenagon Asset Management S.A.. Company insiders that have sold Voyager Therapeutics company stock in the last year include Allison Dorval, Andre Turenne, and Omar Khwaja.
View insider buying and selling activity for Voyager Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Voyager Therapeutics stock?

VYGR stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Fiduciary Trust Co., Belvedere Trading LLC, UBS Group AG, Connor Clark & Lunn Investment Management Ltd., IndexIQ Advisors LLC, and WINTON GROUP Ltd.
View insider buying and selling activity for Voyager Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Voyager Therapeutics' stock price today?

One share of VYGR stock can currently be purchased for approximately $2.87.

How much money does Voyager Therapeutics make?

Voyager Therapeutics has a market capitalization of $108.94 million and generates $171.13 million in revenue each year. The company earns $36.74 million in net income (profit) each year or ($2.48) on an earnings per share basis.

How many employees does Voyager Therapeutics have?

Voyager Therapeutics employs 177 workers across the globe.

What is Voyager Therapeutics' official website?

The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

Where are Voyager Therapeutics' headquarters?

Voyager Therapeutics is headquartered at 75 SIDNEY STREET, CAMBRIDGE MA, 02139.

How can I contact Voyager Therapeutics?

Voyager Therapeutics' mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-5340 or via email at [email protected].


This page was last updated on 12/2/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.